Chalice Brands Ltd.
Chalice Brands Ltd.
Your view on CHALF
Overview
What the company does, where it operates, and who runs it.
About Chalice Brands Ltd.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Jeffrey Yapp
- Headquarters
- 82 Richmond Street East, Toronto, ON, CA
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Jeffrey Yapp
- Headquarters
- 82 Richmond Street East, Toronto, ON, CA
Chalice Brands Ltd. engages in the retail, production, processing, wholesale, and distribution of cannabis products.
It owns, operates, and manages a network of sixteen retail dispensaries in Oregon, including six operate under the flagship dispensary banner Chalice Farms; five operate under the banner of Homegrown Oregon; four under the banner of Cannabliss and Co; and one under the banner of Left Coast Connections.
The company also provides Private Stash distillate vaporizer cartridges and single serve fruit chew blast product under the Golden and Chalice brands, as well as ethanol extract products under the RXO brand name and a live resin and distillate vaporizer cartridge under the brand name of Elysium Fields.
In addition, it manufactures and sells oil products under the brand names Chalice, Golden, Private Stash, Elysium Fields, and Jackpot. The company was formerly known as Golden Leaf Holdings Ltd. and changed its name to Chalice Brands Ltd. in May 2021. Chalice Brands Ltd. is based in Toronto, Canada.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Chalice Brands Ltd., and the rating behind it. CHALF last traded at $0.0001; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Chalice Brands Ltd.. Starting points for Chalice Brands Ltd.: beta 6.75 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Chalice Brands Ltd.. Chalice Brands Ltd. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Chalice Brands Ltd.. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Chalice Brands Ltd.. Chalice Brands Ltd. has reported as a listed company since 2016. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Chalice Brands Ltd. valued side by side against its closest peers. Chalice Brands Ltd. is measured against Drug Manufacturers - Specialty & Generic peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Chalice Brands Ltd., and how their positions are changing. At a $6,660 market value, institutional positions materially move Chalice Brands Ltd.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Chalice Brands Ltd. executives and directors. Shares of Chalice Brands Ltd. have traded between $0.0000 and $0.0001 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Chalice Brands Ltd.. Chalice Brands Ltd. is a $6,660 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Chalice Brands Ltd.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Chalice Brands Ltd.. Coverage tracks Chalice Brands Ltd. within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.